Methods and compositions for transforming cells

• US 5,928,914 A
• Filed: 11/05/1996
• Issued: 07/27/1999
• Est. Priority Date: 06/14/1996
• Status: Expired due to Term

• Current Assignee: Massachusetts Institute of Technology
• Original Assignee: Albert Einstein College of Medicine of Yeshiva University, Massachusetts Institute of Technology
• Inventors: Leboulch, Philippe, Takekoshi, Ken Julian, Westerman, Karen, Bouhassira, Eric
• Primary Examiner(s): LEITH, NANCY J
• Application Number:
  US08/743,796
• Time in Patent Office: 994 Days
• Field of Search: 435/172.3, 435/370.1, 435/183, 435/69.1, 435/70.1, 536/23.1
• US Class Current: 435/456
• CPC Class Codes: C07K 14/805 Haemoglobins; Myoglobins
• CPC Class Codes: C12N 15/64 General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 15/90 Stable introduction of foreign DNA into chromosome
• CPC Class Codes: C12N 2740/13043 viral genome or elements thereof as genetic vector

Abstract

Methods and compositions for transforming cells, resulting in efficient and stable site-specific integration of transgenes, are disclosed. Transformation is achieved by introducing into a cell an acceptor vector, preferably a retroviral vector, which integrates into the genome of the cell. The acceptor vector comprises two incompatible lox sequences, L1 and L2. A donor vector is then introduced into the cell comprising a transgene flanked by the same L1 and L2 sequences. Stable gene transfer is initiated by contacting the lox L1 and L2 sequences with Cre recombinase.

Claims

1. A method of causing site-specific recombination in a mammalian cell comprising contacting a recombinase with (a) an acceptor vector which is integrated into the genome of said mammalian cell, said acceptor vector comprising two lox sequences, L1 and L2, which can not recombine with one another, and (b) a donor vector which is not integrated into the genome of said mammalian cell, said donor vector being present in an amount in excess of said integrated acceptor vector, wherein said donor vector comprises a selected DNA flanked by the same L1 and L2 sequences contained in the acceptor vector, or sequences which can recombine with these L1 and L2 sequences, thereby causing transfer of the selected DNA from the donor vector into the acceptor vector by recombination at the L1 and L2 sequences.

2. The method of claim 1 wherein the acceptor vector is selected from the group consisting of retroviral vectors and adeno-associated vectors.

3. The method of claim 1 wherein L1 and L2 differ by one or more point mutations in their spacer sequences.

4. The method of claim 1 wherein L1 and L2 comprise the LoxP1 and Lox511 nucleotide sequences (SEQ ID NOS:

1 and

     2), respectively, and the recombinase is Cre.

5. The method of claim 1 wherein acceptor vector is a retroviral vector.

6. A method of transforming a cell with a selected DNA comprising, in any order, the steps of:

(a) introducing into the cell an acceptor vector which integrates into the genome of the cell, the acceptor vector comprising two incompatible lox sequences, L1 and L2, which can not recombine with one another;

(b) introducing into the cell a donor vector comprising the selected DNA flanked by the same L1 and L2 sequences contained in the acceptor vector or sequences which can recombine with these L1 and L2 sequences, wherein said donor vector is introduced in an amount in excess of said acceptor vector; and

(c) contacting L1 and L2 with Cre, thereby causing transfer of the selected DNA from the donor vector into the acceptor vector.

7. The method of claim 6 wherein the acceptor vector is an adeno-associated viral vector.

8. The method of claim 6 wherein L1 and L2 differ by at least one nucleotide addition, deletion or substitution in their spacer sequences.

9. The method of claim 6 wherein either L1 or L2 comprises the LoxP1 nucleotide sequence (SEQ ID NO:

1).

10. The method of claim 6 wherein either L1 or L2 comprises the Lox511 nucleotide sequence (SEQ ID NO:

2).

11. The method of claim 6 wherein L1 and L2 comprise the LoxP1 and Lox511 nucleotide sequences (SEQ ID NOS:

1 and

     2), respectively.

12. The method of claim 6 wherein L1 and L2 have the same orientation.

13. The method of claim 6 further comprising the step of introducing into the cell a gene encoding Cre recombinase.

14. The method of claim 13 wherein the gene encoding Cre recombinase is contained in an expression vector.

15. The method of claim 13 wherein the gene encoding Cre recombinase is contained in either the acceptor vector or the donor vector.

16. The method of claim 6 wherein the donor vector is introduced into the cell by electroporation.

17. The method of claim 13 wherein both the donor vector and the gene encoding Cre recombinase are introduced into the cell by electroporation.

18. The method of claim 6 wherein the selected DNA is a transgene encoding a therapeutic protein.

19. The method of claim 18 wherein the protein is β

-globin.

20. The method of claim 6 wherein the donor vector, acceptor vector, or both the donor and acceptor vectors further comprise a selectable marker gene.

21. A Cre/lox mediated gene transfer system comprising:

(a) an acceptor vector which can integrate into the genome of a host cell, the acceptor vector comprising two lox sequences, L1 and L2, which can not recombine with one another;

(b) a donor vector comprising a transgene flanked by the same L1 and L2 sequences contained in the acceptor vector, or sequences which can recombine with these L1 and L2 sequences; and

(c) a transient expression vector encoding a recombinase which can catalyze recombination at the L1 and L2 sequences.

22. The system of claim 21 wherein the acceptor vector is selected from the group consisting of a retroviral vector and an adeno-associated vector.

23. The system of claim 21 wherein L1 and L2 differ by one or more point mutations in their spacer sequences.

24. The system of claim 21 wherein L1 and L2 comprise the LoxP1 and Lox511 nucleotide sequences (SEQ ID NOS:

1 and

     2), respectively.